Published in

SAGE Publications, Journal of the Royal College of Physicians of Edinburgh, 3(41), p. 224-228, 2011

DOI: 10.4997/jrcpe.2011.310

Links

Tools

Export citation

Search in Google Scholar

Ring-fencing a budget for cancer drugs: is it fair?

Journal article published in 2011 by J. Graham, J. Cassidy, D. Hughes ORCID, M. Duerden
This paper was not found in any repository, but could be made available legally by the author.
This paper was not found in any repository, but could be made available legally by the author.

Full text: Unavailable

Green circle
Preprint: archiving allowed
Green circle
Postprint: archiving allowed
Green circle
Published version: archiving allowed
Data provided by SHERPA/RoMEO

Abstract

Ring-fencing is defined as protecting funds for use in a specific area. In the National Health Service in the UK, various methods to ring-fence cancer have been employed over the years; more recently the Cancer Drugs Fund in England has enabled cancer drugs that would not normally be considered cost-effective to be provided to patients. This has created variation in provision between England and the devolved countries. While some would argue that ring-fencing allows major advances to be made in the treatment of a particular condition, others would argue that it is intrinsically unfair. In this debate, Graham and Cassidy have written an article arguing the affirmative position and Hughes and Duerden were invited to respond directly to their arguments. As with all the RCPE's 'Current controversies', the authors have been asked to take a deliberately polarised position and so the views they express may be somewhat overstated.